艾叶总提物、总黄酮及圣草酚通过抑制NF-κB与毒力因子改善幽门螺杆菌胃损伤
该研究比较艾叶总提物(AT)、富集黄酮(AF)及单体圣草酚(EUP)的抗氧化、抗炎与抗幽门螺杆菌作用,并在幽门螺杆菌43504感染SD大鼠模型中验证其抑制毒力因子与NF-κB信号、减轻胃黏膜损伤的效应。
要点
- 艾叶富集黄酮(AF)体外抗氧化与抗幽门螺杆菌活性优于总提物(AT)。
- 圣草酚(EUP)体外杀菌MIC为16-32 μg/mL,体内高剂量溃疡抑制率达87.50%。
- AT、AF、EUP均降低胃细菌负荷、毒力因子及炎症因子,机制涉及抑制NF-κB。
核心结论
- AT、AF和EUP在体内外均可抑制胃黏膜幽门螺杆菌,并通过调控NF-κB信号与毒力因子减轻炎症和溃疡损伤,对幽门螺杆菌相关胃炎显示潜在疗效。
研究设计与样本
- 研究采用UPLC-QE-MS分析AT与AF的黄酮谱,体外用ABTS与DPPH法评价抗氧化,RAW264.7与GES-1细胞评价抗炎并测定MIC与MBC,体内采用幽门螺杆菌43504感染SD大鼠模型,通过Western blotting与qPCR探讨机制。
主要发现
- AF黄酮富集度为86.6%,高于AT的18.7%,且DPPH(IC50=133.8±2.739 μg/ml)与ABTS(IC50=50.83±2.071 μg/ml)抗氧化活性更优。
- AF抗幽门螺杆菌MIC=320 μg/mL,EUP杀菌MIC=16-32 μg/mL。
- 在感染SD大鼠模型中,AT、AF、EUP均显著降低胃细菌负荷与溃疡面积,EUP高剂量溃疡抑制率为87.50%(p<0.001)。
- 各治疗均显著降低血浆毒力因子CagA、VacA及促炎细胞因子IL-1β、IL-6、IL-8、TNF-α水平,并提高SOD活性、降低MPO与MDA。
- 机制上通过抑制NF-κB通路发挥对幽门螺杆菌诱导炎症与溃疡的保护作用。
关键数值与推荐
- AF的DPPH IC50=133.8±2.739 μg/ml,ABTS IC50=50.83±2.071 μg/ml。
- AF抗幽门螺杆菌MIC=320 μg/mL;EUP杀菌MIC=16-32 μg/mL。
- EUP高剂量溃疡抑制率87.50%(p<0.001)。
临床怎么用
- 艾叶富集黄酮与圣草酚可作为幽门螺杆菌相关胃炎辅助干预的潜在候选,但需在临床研究中进一步验证剂量与安全性。
- 机制上可关注NF-κB通路与毒力因子CagA、VacA作为疗效监测的潜在靶点。
局限性
- 研究仅基于幽门螺杆菌43504感染的SD大鼠模型与体外细胞实验,尚未提供人体临床数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Artemisia argyi Folium has been used to treat gastrointestinal disorders like gastritis. Based on centuries-old folk practices, its aerial parts are made into decoctions, infusions, or moxibustion agents to relieve epigastric pain, reduce inflammation, and regulate digestive functions. AIM OF THE STUDY: This study aimed to enrich and identify the flavonoid components, along with the active monomer eupatilin, from Artemisia argyi Folium. We aimed to compare their anti-inflammatory and antioxidant properties, assess their in vitro impact on Helicobacter pylori, and clarify their potential in vivo effects on the inhibition of virulence factors and NF-κB signaling activity. MATERIALS AND METHODS: The flavonoid profiles of two Artemisia argyi Folium extracts (AT and AF) were analyzed using UPLC-QE-MS. The antioxidant activities were evaluated in vitro using ABTS and DPPH assays; the anti-inflammatory effects were assessed employing RAW264.7 and GES-1 cell lines, and the MIC and MBC were determined. The therapeutic efficacy of AT, AF, and EUP against infection and gastric mucosal injury was investigated in H.pylori 43504-infected SD rat model. To probe the mechanisms of action, Western blotting and qPCR analyses were performed. RESULTS: Comprehensive flavonoid profiling has revealed that enriched A. argyi flavonoids (AF, 86.6 %) possess significantly higher levels than total extracts (AT, 18.7 %) and demonstrate superior in vitro antioxidant activity, as evidenced by DPPH (IC50 = 133.8 ± 2.739 μg/ml) and ABTS (IC50 = 50.83 ± 2.071 μg/ml) assays, as well as anti-H. pylori activity (MIC = 320 μg/mL). The active monomer eupatilin (EUP) exhibits significant bactericidal activity (MIC = 16-32 μg/mL). In an H. pylori-infected SD rat model, all treatments (AT, AF, EUP) significantly reduced gastric bacterial load and ulcer area (e.g., EUP high-dose ulcer inhibition rate: 87.50 %, p < 0.001). They also markedly lowered plasma levels of virulence factors (CagA, VacA) and pro-inflammatory cytokines (IL-1β, IL-6, IL-8, TNF-α). Treatments also ameliorated gastric damage, enhanced antioxidant enzyme (SOD) activity, and reduced oxidative stress (MPO, MDA). Mechanistically, protection against H. pylori-induced inflammation and ulceration occurred via suppression of the NF-κB pathway. CONCLUSIONS: This study provides in vivo and vitro confirmation that AT, AF, and EUP can effectively inhibit H. pylori in the gastric mucosa. By regulating the NF-κB signaling pathway and modulating virulence factors, it significantly reduces tissue damage in inflamed stomach areas, showing potential therapeutic efficacy for H. pylori-associated gastritis.
引用
- Zheng C, Du K, Tan B, et al. Amelioration of Helicobacter pylori-induced gastric injury by Artemisia argyi Folium total extract, its total flavonoids, and eupatilin through suppression of NF-κB signaling and virulence factors. J Ethnopharmacol. 2025. PMID: 41275937. doi:10.1016/j.jep.2025.120945
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。